Hyerim Kang, Ph.D.
Postdoctoral Associate
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 273-6268
Business Email:
h.kang@ufl.edu
About Hyerim Kang
Hyerim Kang, Ph.D., is a Post-Doctoral associate in the Department of Pharmaceutical Outcomes and Policy. She received her PharmD and Ph.D. at the Sungkyunkwan University of South Korea, School of Pharmacy, Pharmaceutical Policy & Outcomes Research. Her research centers on the health outcomes studies of medications as well as the cost-effectiveness of new medications. She is enthusiastic about investigating questions associated with the safety and clinical effectiveness of pharmaceuticals and, particularly, how a medication affects the health outcomes in real-world clinical care settings.
Publications
2023
Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism.
Clinical and translational science.
16(6):946-954
[DOI] 10.1111/cts.13510.
[PMID] 36891985.
2023
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.
Clinical and translational science.
16(1):128-139
[DOI] 10.1111/cts.13433.
[PMID] 36200137.
2023
Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding.
Journal of managed care & specialty pharmacy.
29(11):1219-1230
[DOI] 10.18553/jmcp.2023.29.11.1219.
[PMID] 37889866.
2023
Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding.
Research and practice in thrombosis and haemostasis.
7(3)
[DOI] 10.1016/j.rpth.2023.100131.
[PMID] 37159747.
2023
Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
The Annals of pharmacotherapy.
57(12):1349-1360
[DOI] 10.1177/10600280231155489.
[PMID] 36999519.
2022
Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
Journal of internal medicine.
291(6):877-885
[DOI] 10.1111/joim.13462.
[PMID] 35192737.
2022
Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
Clinical pharmacology and therapeutics.
112(1):133-145
[DOI] 10.1002/cpt.2611.
[PMID] 35420702.
Contact Details
Phones:
- Business:
- (352) 273-6268
Emails:
- Business:
- h.kang@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610